Actue Coronary Syndrome Clinical Trial
Official title:
Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With Actue Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Limited data are available on the efficacy of beta-blocker therapy for secondary prevention in Actue Coronary Syndrome(ACS) patients. This study sought to investigate the association of beta-blocker therapy at discharge with clinical outcomes in patients with ACS after percutaneous coronary intervention (PCI).
The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines
recommend beta-blockers for secondary prevention in patients with ACS without regard to
reperfusion therapy. However, evidence supporting this recommendation originated from studies
conducted before the introduction of reperfusion therapy or studies in patients treated with
fibrinolysis. In the present era of PCI, there are no prospective randomized studies looking
at the effects of long-term beta-blocker therapy on clinical outcomes in ACS patients.
Moreover, results from registry data and post-hoc analysis on beta-blocker therapy in
patients undergoing PCI are inconsistent.
In particular, the beneficial effect of long-term beta-blocker therapy has not been well
established in patients with relatively low risk, such as preserved left ventricular systolic
function or single-vessel disease. Therefore, we investigated the association of beta-blocker
therapy at discharge with clinical outcomes in ACS patients after PCI.
;